Loading...
XSTO
CAMX
Market cap3.39bUSD
Apr 14, Last price  
562.00SEK
1D
3.31%
1Q
-3.19%
Jan 2017
428.04%
IPO
816.18%
Name

Camurus AB

Chart & Performance

D1W1MN
XSTO:CAMX chart
No data to show
P/E
77.24
P/S
17.72
EPS
7.28
Div Yield, %
—
Shrs. gr., 5y
5.20%
Rev. gr., 5y
77.63%
Revenues
1.87b
+8.78%
95,204,000197,716,000208,207,000154,799,000113,737,00054,308,00049,321,000105,605,000335,997,000600,570,000956,340,0001,716,850,0001,867,581,000
Net income
428m
-0.71%
13,317,00099,235,00048,346,000-159,542,000-80,993,000-190,574,000-234,676,000-289,865,000-167,265,000-90,446,00055,553,000431,442,000428,394,000
CFO
388m
-36.07%
24,735,000163,064,00069,429,000-5,657,000-207,788,000-203,068,000-274,084,000-404,364,000-238,832,000-143,427,000101,199,000606,878,000387,990,000
Earnings
May 06, 2025

Profile

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
URL
https://www.camurus.com/
IPO date
Dec 03, 2015
Employees
199
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,867,581
8.78%
1,716,850
79.52%
956,340
59.24%
Cost of revenue
1,396,848
1,184,495
885,812
Unusual Expense (Income)
NOPBT
470,733
532,355
70,528
NOPBT Margin
25.21%
31.01%
7.37%
Operating Taxes
124,128
117,862
17,572
Tax Rate
26.37%
22.14%
24.91%
NOPAT
346,605
414,493
52,956
Net income
428,394
-0.71%
431,442
676.63%
55,553
-161.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,311,449
32,692
58,492
BB yield
-3.87%
-0.11%
-0.42%
Debt
Debt current
9,906
10,894
9,574
Long-term debt
24,182
38,120
42,860
Deferred revenue
(1,737)
Other long-term liabilities
21,567
32,612
12,532
Net debt
(2,818,611)
(1,140,826)
(520,102)
Cash flow
Cash from operating activities
387,990
606,878
101,199
CAPEX
(27,613)
(9,190)
(1,905)
Cash from investing activities
(29,371)
(10,127)
5,382
Cash from financing activities
1,300,668
28,763
43,705
FCF
133,395
399,617
36,479
Balance
Cash
2,852,699
1,189,840
565,539
Long term investments
6,997
Excess cash
2,759,320
1,103,998
524,719
Stockholders' equity
(123,580)
(551,980)
(979,062)
Invested Capital
3,451,872
2,102,100
2,001,727
ROIC
12.48%
20.20%
2.71%
ROCE
14.14%
34.34%
6.88%
EV
Common stock shares outstanding
59,921
57,497
55,067
Price
565.50
5.11%
538.00
112.98%
252.60
67.51%
Market cap
33,885,561
9.54%
30,933,648
122.39%
13,909,925
69.40%
EV
31,066,950
29,792,822
13,389,823
EBITDA
485,370
546,342
83,464
EV/EBITDA
64.01
54.53
160.43
Interest
1,084
1,275
1,526
Interest/NOPBT
0.23%
0.24%
2.16%